Efficiency of a second‐generation HIV‐1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations

A subnanomolar inhibitor of human immunodeficiency virus type 1 (HIV‐1) protease, designated QF34, potently inhibits the wild‐type and drug‐resistant enzyme. To explain its broad activity, the binding of QF34 to the wild‐type HIV‐1 protease is investigated by molecular dynamics simulations and compared to the binding of two inhibitors that are used clinically, saquinavir (SQV) and indinavir (IDV). Analysis of the flexibility of protease residues and inhibitor segments in the complex reveals that segments of QF34 were more mobile during the dynamics studies than the segments of SQV and IDV. The dynamics of hydrogen bonding show that QF34 forms a larger number of stable hydrogen bonds than the two inhibitors that are used clinically. Absolute binding free energies were calculated with molecular mechanics–generalized Born surface area (MM–GBSA) methodology using three protocols. The most consistent results were obtained using the single‐trajectory approach, due to cancellation of errors and inadequate sampling in the separate‐trajectory protocols. For all three inhibitors, energy components in favor of binding include van der Waals and electrostatic terms, whereas polar solvation and entropy terms oppose binding. Decomposition of binding energies reveals that more protease residues contribute significantly to the binding of QF34 than to the binding of SQV and IDV. Moreover, contributions from protease main chains and side chains are balanced in the case of QF34 (52:48 ratio, respectively), whereas side chain contributions prevail in both SQV and IDV (main‐chain:side‐chain ratios of 41:59 and 45:55, respectively). The presented results help explain the ability of QF34 to inhibit multiple resistant mutants and should be considered in the design of broad‐specificity second‐generation HIV‐1 protease inhibitors. Proteins 2004. © 2004 Wiley‐Liss, Inc.

[1]  David L. Beveridge,et al.  Prediction of the protonation state of the active site aspartyl residues in HIV-1 protease-inhibitor complexes via molecular dynamics simulation , 1993 .

[2]  Charles J. Eyermann,et al.  NMR and X-ray Evidence That the HIV Protease Catalytic Aspartyl Groups Are Protonated in the Complex Formed by the Protease and a Non-Peptide Cyclic Urea-Based Inhibitor , 1994 .

[3]  Themis Lazaridis,et al.  Binding Affinity and Specificity from Computational Studies , 2002 .

[4]  Paolo Carloni,et al.  Conformational flexibility of the catalytic Asp dyad in HIV‐1 protease: An ab initio study on the free enzyme , 2000, Proteins.

[5]  P. Kollman,et al.  Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Surjit B. Dixit,et al.  Free Energy Analysis of ProteinDNA Binding: The EcoRI EndonucleaseDNA Complex , 1999 .

[7]  David A. Case,et al.  Calculations of the Absolute Free Energies of Binding between RNA and Metal Ions Using Molecular Dynamics Simulations and Continuum Electrostatics , 2001 .

[8]  Mark A. Murcko,et al.  Conformational analysis of HIV protease inhibitors. I. Rotation of the amide group adjacent to the P′1 decahydroisoquinoline ring system in ro 31‐8959 and related systems , 1993, J. Comput. Chem..

[9]  Jörg Weiser,et al.  Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) , 1999, J. Comput. Chem..

[10]  M Karplus,et al.  Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility. , 2002, Journal of molecular biology.

[11]  J. Erickson,et al.  Calculation of Relative Binding Free Energies of Peptidic Inhibitors to HIV-1 Protease and Its I84V Mutant , 1998 .

[12]  A Wlodawer,et al.  Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. , 1998, Annual review of biophysics and biomolecular structure.

[13]  P. Kollman,et al.  Continuum Solvent Studies of the Stability of DNA, RNA, and Phosphoramidate−DNA Helices , 1998 .

[14]  J. Leis,et al.  Development of Drug Resistance to HIV-1 Protease Inhibitors (*) , 1995, The Journal of Biological Chemistry.

[15]  Bhyravabhotla Jayaram,et al.  Free Energy Analysis of Protein-DNA Binding , 1999 .

[16]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[17]  J. Nadler.  New anti-HIV protease inhibitors provide more treatment options. , 2003, AIDS patient care and STDs.

[18]  S. Rick,et al.  Molecular mechanisms of resistance: Free energy calculations of mutation effects on inhibitor binding to HIV‐1 protease , 1998, Protein science : a publication of the Protein Society.

[19]  Junmei Wang,et al.  How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? , 2000, J. Comput. Chem..

[20]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[21]  K. Ingold,et al.  Two-step binding mechanism for HIV protease inhibitors. , 1992, Biochemistry.

[22]  Pavel Hobza,et al.  Molecular dynamics simulations and thermodynamics analysis of DNA-drug complexes. Minor groove binding between 4',6-diamidino-2-phenylindole and DNA duplexes in solution. , 2003, Journal of the American Chemical Society.

[23]  P. Kollman,et al.  Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .

[24]  Milan Soucek,et al.  A phenylnorstatine inhibitor binding to HIV-1 protease: geometry, protonation, and subsite-pocket interactions analyzed at atomic resolution. , 2004, Journal of medicinal chemistry.

[25]  S. Alavi.  Molecular simulations , 1998, Current Biology.

[26]  P A Kollman,et al.  An analysis of the interactions between the Sem-5 SH3 domain and its ligands using molecular dynamics, free energy calculations, and sequence analysis. , 2001, Journal of the American Chemical Society.

[27]  Dale J. Kempf,et al.  In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor , 1998, Journal of Virology.

[28]  I. Luque,et al.  Structure-based thermodynamic analysis of HIV-1 protease inhibitors. , 1997, Biochemistry.

[29]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[30]  Piotr Cieplak,et al.  Molecular dynamics and free energy analyses of cathepsin D-inhibitor interactions: insight into structure-based ligand design. , 2002, Journal of medicinal chemistry.

[31]  A. Wlodawer,et al.  Structure-based inhibitors of HIV-1 protease. , 1993, Annual review of biochemistry.

[32]  N. Parkin,et al.  Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors , 2003, Antimicrobial Agents and Chemotherapy.

[33]  M. Parrinello,et al.  Ab initio molecular dynamics-based assignment of the protonation state of pepstatin A/HIV-1 protease cleavage site. , 2001, Journal of the American Chemical Society.

[34]  W. C. Still,et al.  Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .

[35]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[36]  P. Kollman,et al.  Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. , 2000, Journal of medicinal chemistry.

[37]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[38]  D. Case,et al.  Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. , 2003, Journal of molecular biology.

[39]  C. Debouck,et al.  Inhibitor binding to the Phe53Trp mutant of HIV-1 protease promotes conformational changes detectable by spectrofluorometry. , 1993, Biochemistry.

[40]  B. Jayaram,et al.  Free energy component analysis for drug design: a case study of HIV-1 protease-inhibitor binding. , 2001, Journal of medicinal chemistry.

[41]  Richard H. Henchman,et al.  Revisiting free energy calculations: a theoretical connection to MM/PBSA and direct calculation of the association free energy. , 2004, Biophysical journal.

[42]  S. Rick,et al.  Reaction path and free energy calculations of the transition between alternate conformations of HIV‐1 protease , 1998, Proteins.

[43]  Arun K. Ghosh,et al.  A Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor, UIC-94003 (TMC-126), and Selection of a Novel (A28S) Mutation in the Protease Active Site , 2002, Journal of Virology.

[44]  L. Kuo,et al.  Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. , 1996, The Journal of biological chemistry.

[45]  Thomas Klimkait,et al.  Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains. , 2002, Journal of molecular biology.

[46]  P. Kollman,et al.  Biomolecular simulations: recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid noncovalent interactions. , 2001, Annual review of biophysics and biomolecular structure.

[47]  M. Gilson,et al.  The statistical-thermodynamic basis for computation of binding affinities: a critical review. , 1997, Biophysical journal.

[48]  Alexander Wlodawer,et al.  Rational approach to AIDS drug design through structural biology. , 2002, Annual review of medicine.

[49]  P. Kollman,et al.  Computational Alanine Scanning To Probe Protein−Protein Interactions: A Novel Approach To Evaluate Binding Free Energies , 1999 .

[50]  D. Beveridge,et al.  Free energy via molecular simulation: applications to chemical and biomolecular systems. , 1989, Annual review of biophysics and biophysical chemistry.

[51]  I. Weber,et al.  Comparative analysis of the sequences and structures of HIV‐1 and HIV‐2 proteases , 1991, Proteins.

[52]  Rieko Ishima,et al.  Protein dynamics from NMR , 2000, Nature Structural Biology.

[53]  Ursula Rothlisberger,et al.  Drug resistance in HIV‐1 protease: Flexibility‐assisted mechanism of compensatory mutations , 2002, Protein science : a publication of the Protein Society.

[54]  A. Velázquez‐Campoy,et al.  HIV-1 protease inhibitors: enthalpic versus entropic optimization of the binding affinity. , 2000, Biochemistry.

[55]  M. Hatada,et al.  Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.

[56]  D. Underwood,et al.  Advances in automated docking applied to human immunodeficiency virus type 1 protease. , 1994, Methods in Enzymology.

[57]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[58]  I. Pichová,et al.  Configurations of diastereomeric hydroxyethylene isosteres strongly affect biological activities of a series of specific inhibitors of human-immunodeficiency-virus proteinase. , 1997, European journal of biochemistry.

[59]  J A McCammon,et al.  Theory of biomolecular recognition. , 1998, Current opinion in structural biology.

[60]  M. Karplus,et al.  Proteins: A Theoretical Perspective of Dynamics, Structure, and Thermodynamics , 1988 .

[61]  Themis Lazaridis,et al.  Contributions to the binding free energy of ligands to avidin and streptavidin , 2002, Proteins.

[62]  T. Bhat,et al.  Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. , 1995, Structure.

[63]  I. Pichová,et al.  Potency comparison of peptidomimetic inhibitors against HIV-1 and HIV-2 proteinases: design of equipotent lead compounds. , 1997, Archives of biochemistry and biophysics.

[64]  J. Falloon,et al.  JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Dale J. Kempf,et al.  ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease , 1998, Antimicrobial Agents and Chemotherapy.

[66]  D. Case,et al.  Theory and applications of the generalized born solvation model in macromolecular simulations , 2000, Biopolymers.

[67]  P A Kollman,et al.  Structure and thermodynamics of RNA-protein binding: using molecular dynamics and free energy analyses to calculate the free energies of binding and conformational change. , 2000, Journal of molecular biology.

[68]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[69]  A Tropsha,et al.  Relative binding free energies of peptide inhibitors of HIV-1 protease: the influence of the active site protonation state. , 1995, Journal of medicinal chemistry.

[70]  I. Luque,et al.  Molecular basis of resistance to HIV-1 protease inhibition: a plausible hypothesis. , 1998, Biochemistry.

[71]  J. Erickson,et al.  Structural mechanisms of HIV drug resistance. , 1996, Annual review of pharmacology and toxicology.

[72]  John P. Overington,et al.  X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes , 1989, Nature.

[73]  J. Louis,et al.  Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function. , 1999, Structure.

[74]  S. Noskov,et al.  Free energy decomposition of protein-protein interactions. , 2001, Biophysical journal.

[75]  Holger Gohlke,et al.  Converging free energy estimates: MM‐PB(GB)SA studies on the protein–protein complex Ras–Raf , 2004, J. Comput. Chem..